Renova Pharmaceuticals has announced the commercial launch of its first 3 US Food and Drug Administration (FDA)-approved generic products in the US: L-Glutamine for Oral Solution, Dimethyl Sulfoxide (DMSO) Irrigation, 50 percent, and Ascorbic Acid Injection.

These launches represent a significant milestone for Renova, marking the company's transition from building its development and regulatory pipeline to establishing a growing commercial presence in the US generics market.

Renova's Dimethyl Sulfoxide (DMSO) irrigation, 50 percent received FDA approval with Competitive Generic Therapy (CGT) designation, reflecting the company's strategy of pursuing differentiated products where additional generic competition can benefit the US healthcare system.

Seshu Akula, CEO, Renova, USA, said, "This is a very proud moment for all of us at Renova. Launching our first 3 products represents the beginning of an exciting new phase in our journey. Our vision is to build Renova into a differentiated and trusted US generics company focused on technically challenging products, reliable supply and meaningful market opportunities. I am extremely grateful to our teams, partners, customers and stakeholders whose commitment has helped us reach this milestone."

Renova is building a diversified portfolio across sterile injectables, ophthalmics, complex generics and select oral dosage forms, with additional products progressing through development and FDA review.

Dr. Lloyd Balajadia, President, Lloyds Group, said, "The launch of Renova's first 3 products is a proud achievement for the entire Lloyds Group and demonstrates the strength of collaboration across development, manufacturing, regulatory, quality and commercialisation. We remain committed to supporting Renova's growth and its mission to deliver high-quality, accessible medicines to the US market."

Renova plans to continue expanding its US portfolio through internal development, strategic partnerships and targeted product opportunities.